The world can eliminate AIDS by empowering communities and prioritizing human rights. We can end AIDS as a global health threat by 2030.   The World Health Organization (WHO) joined forces with partners and communities to commemorate World AIDS Day 2024 (1 December), ...

Mpox is endemic in the Democratic Republic of the Congo (DRC), with cases rising over the past decade. Children were the most severely affected in the 2023 outbreak, which saw over 14,000 cases and 600 deaths.1 Despite the deployment of the modified vaccinia ...

touchINFECTIOUS DISEASES were thrilled to speak with Professor Barbara Van Der Pol (Professor of Medicine and Public Health, University of Alabama at Birmingham, AL) about her perspectives on recent advances in sexually transmitted infection (STI) diagnostic tools, management and breaking ...

As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.

In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.

The European Region is a global vaccine leader, boasting a “strong research ecosystem” and a competitive market, expected to achieve a volume of €16.32 billion by 2029. Through efforts to keep pace with the “unprecedented acceleration” of life science innovation, the landscape attracts investment and political support as leaders recognise the value of vaccination as a cost-effective intervention and a means of demonstrating health leadership.

In a real-world study from Ontario, researchers confirmed that a single dose of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine offers 58% protection against mpox infection.

Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.